SPOTLIGHT: FDA approves Wyeth's Torisel

The FDA has approved Wyeth's Torisel for advanced renal cell carcinoma. In Phase III, Torisel improved median overall survival by 49 percent compared to interferon-alpha. Release

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.